Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Phase 2

Completed

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-01-27

Last Posted Date: 2012-03-15

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 44

Registration Number: NCT00003335

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-21

Lead Sponsor: UNICANCER

Target Recruit Count: 179

Registration Number: NCT00003650

Locations: 🇫🇷
Centre Leon Berard, Lyon, France

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Phase 3

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2011-01-21

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1500

Registration Number: NCT00003728

Locations: 🇵🇹
Hospital Escolar San Joao, Porto, Portugal
🇵🇹
Instituto Portugues de Oncologia Centro do Porto, SA, Porto, Portugal
🇫🇷
CHR de Besancon - Hopital Saint-Jacques, Besancon, France

and more 20 locations

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 6

Registration Number: NCT00003336

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease

Phase 2

Completed

Conditions: Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 390

Registration Number: NCT00003913

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 20 locations

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Phase 4

Completed

Conditions: Heart Transplantation

Interventions: Drug: Daclizumab
Drug: Methylprednisolone
Drug: Placebo
Drug: Mycophenolate mofetil
Drug: cyclosporine

First Posted Date: 2002-10-25

Last Posted Date: 2016-06-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 434

Registration Number: NCT00048165

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

Phase 4

Withdrawn

Conditions: Demyelinating Disorders
Multiple Sclerosis
Optic Neuritis
Myelitis
Neuritis

First Posted Date: 2002-05-17

Last Posted Date: 2018-04-12

Lead Sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute

Registration Number: NCT00037115

Locations: 🇺🇸
MidAmerica Neuroscience Institute, Kansas City, Missouri, United States

The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS

Phase 3

Withdrawn

Conditions: Pneumonia, Pneumocystis Carinii
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00000741

Locations: 🇺🇸
Columbia Presbyterian Med Ctr, New York, New York, United States
🇺🇸
Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
🇺🇸
Duke Univ Med Ctr, Durham, North Carolina, United States

and more 3 locations

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

Phase 2

Terminated

Conditions: End-Stage Renal Disease

Interventions: Drug: Basiliximab
Drug: Cyclosporine
Drug: Tacrolimus
Drug: Sirolimus
Drug: Methylprednisolone
Drug: Prednisone
Drug: Bactrim

First Posted Date: 2001-08-31

Last Posted Date: 2016-10-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 274

Registration Number: NCT00023244

Locations: 🇺🇸
University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸
The Children's Hospital of Buffalo, Buffalo, New York, United States
🇺🇸
Westchester Medical Center, Valhalla, New York, United States

and more 16 locations

Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients

Phase 3

Terminated

Conditions: HIV Infections
Pneumonia, Pneumocystis Carinii

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 240

Registration Number: NCT00000730

Locations: 🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy